Diagnosed with Stage 4 bowel cancer at just 33, the initial treatment Chloe received did not completely eliminate the cancer in her lungs and she has spent the last three years on two different clinical trials.
We need your help to raise $200,000 by midnight tonight so we can fund early-onset bowel cancer research that has the potential to improve survival and help build a path toward a cure.
Bowel cancer is the deadliest cancer and the seventh underlying cause of death overall for Australians aged 25-44.
Bowel Cancer Australia is focused on funding promising, high-impact, early-onset bowel cancer research endeavours to help improve our knowledge and understanding of this disease, including:
the causes of early-onset bowel cancer;
better pathways to diagnosis;
unique needs of younger patients;
new treatment options; and
tailored support and care.
Cutting edge research, like that being undertaken by the team of researchers investigating ROCK-induced early-onset bowel cancer progression, led by Professor Michael Samuel and made possible thanks to donations received through Bowel Cancer Australia’s Annual Giving Day.
Donate now and have your gift MATCHED, so your donation will have DOUBLE the impact.
“People diagnosed with early-onset bowel cancer have a 50% chance that their cancer will recur or spread to other organs following initial intervention, compared to around 30% in people diagnosed with late-onset bowel cancer.
We have evidence that ROCK activity in bowel cancers drives this process by influencing how cancers communicate with their environment. Our project will investigate how this happens.
In a practical sense, this could help us use targeted therapies that block cancer cells from communicating with their environment, in people who are most likely to experience recurrence of their cancer. It could also help us minimise the use of debilitating chemotherapies.” ~ Professor Michael Samuel.
